General

ABL Diagnostics at the Federation of Infection Societies congress

ABL Diagnostics at the Federation of Infection Societies congress Discover the scientific publications from our Innovation team and get more information about new products & services including:  Publication #1 (Poster n°98) Whole Genome Sequencing of Human BK Polyomavirus Using Next-Generation Sequencing View Descamps Veronique1,  Morel Virginie1,  Olivia Ardizzoni,   Amira Doudou,  Chalom Sayada,  Sofiane Mohamed, and Brochot

ABL Diagnostics at the Federation of Infection Societies congress Read More »

Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) is now ABL Diagnostics SA

Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) is now ABL Diagnostics SA On September 1st 2022, Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) merged into ABL Diagnostics SA (ABLD), a worldwide leading international company, listed on Euronext Paris compartment C (ISIN FR001400AHX6), offering innovative and proprietary molecular biology assays and end-to-end

Advanced Biological Laboratories Fedialis SAS (formerly ABL France SAS) is now ABL Diagnostics SA Read More »

WHO algorithm v2021-06 for Tuberculosis resistance now available!

WHO algorithm v2021-06 for Tuberculosis resistance now available! We are pleased to announce the immediate availability of the WHO Catalog of Mutations (version 2021-06) in BacterioChek-TB, intended to be used for Mycobacterium tuberculosis drug resistance assessement. ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574

WHO algorithm v2021-06 for Tuberculosis resistance now available! Read More »

DEEPCHEK® ASSAY 13-PLEX KB DRUG SUSCEPTIBILITY TESTING IS NOW CE-IVD MARKED

We are pleased to announce that our DeepChek® Assay 13-Plex KB Drug Susceptibility Testing, intended to be used for Tuberculosis Drug Resistance assessment through NGS sequencing, is now CE-IVD marked ! ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574 Email : contact@abldiagnostics.com Email 2 : fauvet-girel@ablsa.com Envelope

DEEPCHEK® ASSAY 13-PLEX KB DRUG SUSCEPTIBILITY TESTING IS NOW CE-IVD MARKED Read More »

Presentation of the DeepChek®-HIV Whole Genome Assay at ECCMID 2022

We are pleased to announce a new poster presentation entitled “Evaluation of a commercial assay whole genome HIV-1 using next-generation sequencing” at ECCMID 2022. Link to the poster presentation. Please feel free to contact us to get more information. ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061

Presentation of the DeepChek®-HIV Whole Genome Assay at ECCMID 2022 Read More »

ÉTABLISSEMENTS FAUVET GIREL – RÉSULTATS ANNUELS 2021

ETABLISSEMENTS FAUVET GIREL (FR0000063034 – FAUV – Euronext Paris) publie ses résultats annuels au titre de l’exercice clos le 31 décembre 2021, arrêtés par le Conseil d’administration du 8 février 2022. Les comptes ont été audités par le commissaire aux comptes dont le rapport de certification est en cours d’émission. Résultats annuels 2021 ETABLISSEMENTS FAUVET

ÉTABLISSEMENTS FAUVET GIREL – RÉSULTATS ANNUELS 2021 Read More »

ABL announce a new Distribution Agreement with Geneplus Co Ltd in Thailand

Advanced Biological Laboratories (ABL) S.A. and Geneplus Co Ltd are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Thailand See all the current Distributors ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone :

ABL announce a new Distribution Agreement with Geneplus Co Ltd in Thailand Read More »

Scroll to Top